Therapeutic

Scancell announces “encouraging” early Modi-1 data

Scancell announces “encouraging” early Modi-1 data

In February 2023 Scancell announced completion of a monotherapy dose finding arm of the Phase I/II ModiFY clinical trial. Data demonstrated that the Modi-1 cancer vaccine was “safe and well tolerated” with “encouraging early efficacy” in a head and neck cancer...

Gritstone bio and NCI collaborate on clinical trial

Gritstone bio and NCI collaborate on clinical trial

In February 2023 Gritstone bio and the National Cancer Institute (NCI) of NIH announced a collaboration to evaluate an “autologous T cell therapy expressing a T cell receptor targeting mutated KRAS in combination with Gritstone’s KRAS-directed vaccine candidate”. The...

VBI Vaccines announces Phase II data for HBV therapy

VBI Vaccines announces Phase II data for HBV therapy

In February 2023 VBI Vaccines announced interim data from a Phase II study evaluating a combination treatment of VBI-2601 (BRII-179) and BRII-835 (VIR-2218) in chronically infected HBV patients. The data demonstrates that the therapy was “generally well-tolerated". It...

Cancer vaccines strengthened against aggressive tumours

Cancer vaccines strengthened against aggressive tumours

In research published in Nature biomedical engineering a team of scientists at Northwestern University’s International Institute for Nanotechnology (IIN) explored the effects of structural changes to cancer vaccines. Using chemistry and nanotechnology they changed the...

AC Immune Alzheimer’s vaccine shows promise in early trials

AC Immune Alzheimer’s vaccine shows promise in early trials

Swiss based AC Immune reported in January 2023 that ACI-24.060, its anti-amyloid-beta (Abeta) vaccine, had “elicited an anti-Abeta antibody response” and was “well tolerated” in patients with prodromal Alzheimer’s disease (AD). It will therefore move to a second...

LinKinVax and Gustave Roussy collaborate for human trial

LinKinVax and Gustave Roussy collaborate for human trial

In January 2023 LinKinVax and Gustave Roussy announced a collaboration towards a first-in-human Phase I/IIa clinical trial on a therapeutic vaccine candidate. This vaccine, CD40HVac, will target head and neck cancer associated with human papillomavirus (HPV). The...

UK and BioNTech sign MoU for mRNA cancer therapies

UK and BioNTech sign MoU for mRNA cancer therapies

In January 2023 BioNTech announced that it had signed a Memorandum of Understanding (MoU) with the UK government to “benefit patients”. The goal will be to accelerate clinical trials for personalised mRNA therapeutics with a target of providing personalised cancer...